Completed PHASE3 INTERVENTIONAL NCT00195546

Study Evaluating DVS-233 SR for Treatment of Vasomotor Symptoms Associated With Menopause

A Multicenter, Randomized, Double-Blind, Placebo- and Active-Controlled Study of DVS-233 SR for Treatment of Vasomotor Symptoms Associated With Menopause

Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer

Conditions Menopause

Interventions DVS-233

Updated 6 times since 2017 Last updated: May 31, 2007 Started: Apr 30, 2005 Completion: Jan 31, 2006

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Menopause and is currently completed. Wyeth is now a wholly owned subsidiary of Pfizer leads this study, which shows 6 recorded versions since 2005 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Apr 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Wyeth is now a wholly owned subsidiary of Pfizer

Data source: Wyeth is now a wholly owned subsidiary of Pfizer

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

's-Hertogenbosch, Netherlands , Bloemfontein, South Africa , Bucharest, Romania , Centurion, South Africa , Debrecen, Hungary , Del. Cuauhtemoc, Mexico , Donetsk, Ukraine , Fowey, United Kingdom , Hengelo, Netherlands , Katowice, Poland and 25 more locations